Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on April 18th, 2019 by Elia Lima-Walton, MDPharma R&D
Elseiver’s Elia Lima-Watson, MD explores the phenomenon of automation int he lab beyond just rote tasks. Fascinating developments in this field and others continue to accelerate the discovery process at a dizzying rate.(more…)
Posted on April 17th, 2019 by Frederik van den BroekPharma R&D
Artificial Intelligence, Machine Learning and Deep Learning are on the tip of everyone’s tongues when it comes to acceleration of the pace of discovery The Pharma R&D market is a perfect exemplification of this phenomenon. Medical advancements enabled by such technologies have proven to significantly accelerate discovery processes, saving valuable time and money required for the development of life changing solutions. That being said, there is the reality that human beings with a passion and talent for feeding such mechanisms still and likely always will provide invaluable inputs. In short, we are not to be replaced by these advancements; rather the changes are indicative of a new era of advancement defined by “partnerships” between humans and machines.(more…)
Posted on April 17th, 2019 by Abhinav KumarPharma R&D
Unification across platforms is providing multiple benefits to organizations who pull together massive amounts of data across multiple platforms. Technology is evolving to eliminate data redundancy and silos as evidenced by the collaboration between Elsevier and Lundbeck.(more…)
Posted on April 16th, 2019 by Nicki CatchpolePharma R&D
Go to any conference these days and the number one buzzword is AI. However, despite all the excitement, AI is still talked about in fairly vague terms – with few people able to pin down exactly what they mean by AI. New research from some of my Elsevier colleagues examined this phenomenon.(more…)
Posted on April 13th, 2019 by Nicki CatchpolePharma R&D
Beacon Discovery is a selected member of Elsevier’s The Hive, which is a partnership engine supporting innovation and R&D with emerging biotech startups. Here, Dr. Carleton Sage explains how leveraging the Elsevier suite of solutions in conjunction with an impassioned approach to GCPR research, Beacon Discovery has made significant strides in the discovery process to solve unmet medical needs.(more…)
Posted on April 9th, 2019 by Chris Cheadle PhDPharma R&D
Partnerships between organizations with complementary goals and capabilities are increasingly proving to pave paths towards revolutionary advancements in life sciences. One such partnership is highlighted between Elsevier and Rochester General Hospital at ConTech 2018 in the field of In Silico Disease Modelling.
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.